These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25063763)

  • 21. Molecule of the month. Eltrombopag.
    Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592
    [No Abstract]   [Full Text] [Related]  

  • 22. Thrombopoietin-receptor agonists for immune thrombocytopenia.
    Jansen AJ; Swart RM; te Boekhorst PA
    N Engl J Med; 2011 Dec; 365(23):2240-1. PubMed ID: 22150056
    [No Abstract]   [Full Text] [Related]  

  • 23. Eltrombopag in chronic hepatitis C.
    Mihăilă RG; Cipăian RC
    World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombopoietin-receptor agonists for primary immune thrombocytopenia.
    Imbach P; Crowther M
    N Engl J Med; 2011 Aug; 365(8):734-41. PubMed ID: 21864167
    [No Abstract]   [Full Text] [Related]  

  • 25. Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms.
    Polverelli N; Palandri F; Iacobucci I; Catani L; Martinelli G; Vianelli N
    Br J Haematol; 2013 Apr; 161(1):142-4. PubMed ID: 23278214
    [No Abstract]   [Full Text] [Related]  

  • 26. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
    Jenkins JM; Williams D; Deng Y; Uhl J; Kitchen V; Collins D; Erickson-Miller CL
    Blood; 2007 Jun; 109(11):4739-41. PubMed ID: 17327409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eltrombopag for chronic immune thrombocytopenia.
    Milosevic I; Slade E; Drysdale H;
    Lancet; 2016 Jan; 387(10016):336. PubMed ID: 26842445
    [No Abstract]   [Full Text] [Related]  

  • 28. Current status of thrombopoietic agents.
    Rhodes E; Stasi R
    Expert Rev Hematol; 2010 Apr; 3(2):217-25. PubMed ID: 21083464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eltrombopag for chronic immune thrombocytopenia - Authors' reply.
    Grainger JD;
    Lancet; 2016 Jan; 387(10016):336-337. PubMed ID: 26842444
    [No Abstract]   [Full Text] [Related]  

  • 30. Eltrombopag for secondary failure of platelet recovery post-allogeneic hematopoietic stem cell transplant in children.
    Ali S; Gassas A; Kirby-Allen M; Krueger J; Ali M; Schechter T
    Pediatr Transplant; 2017 Sep; 21(6):. PubMed ID: 28653480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eltrombopag in thrombocytopenia.
    Zimmer J; Hentges F; Andrès E
    N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18326076
    [No Abstract]   [Full Text] [Related]  

  • 32. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
    Kühne T; Imbach P
    Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eltrombopag to allow chemotherapy in a patient with MYH9-related inherited thrombocytopenia and pancreatic cancer.
    Paciullo F; Bury L; Gresele P
    Int J Hematol; 2020 Nov; 112(5):725-727. PubMed ID: 32557126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eltrombopag in patients with chronic liver disease.
    Giannini EG; Afdhal NH
    Expert Opin Pharmacother; 2013 Apr; 14(5):669-78. PubMed ID: 23452139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment of amegakaryocytic thrombocytopenia with eltrombopag in a patient with systemic lupus erythematosus (SLE).
    Cela I; Miller IJ; Katz RS; Rizman A; Shammo JM
    Clin Adv Hematol Oncol; 2010 Nov; 8(11):806-9. PubMed ID: 21326158
    [No Abstract]   [Full Text] [Related]  

  • 36. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D;
    N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The new thrombopoietic agenda: impact on leukemias and MDS.
    Bussel JB
    Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations.
    Serebruany VL; Eisert C; Sabaeva E; Makarov L
    Am J Ther; 2010; 17(1):68-74. PubMed ID: 19451811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Lisman T; Porte RJ
    N Engl J Med; 2012 Nov; 367(21):2055-6. PubMed ID: 23171114
    [No Abstract]   [Full Text] [Related]  

  • 40. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Violi F; Pignatelli P
    N Engl J Med; 2012 Nov; 367(21):2056. PubMed ID: 23171115
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.